secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0002007919-26-000010
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx reports 20% ORR with ozekibart combo in late-line CRC; BLA submitted for chondrosarcoma
--------------------------------------------------------------------------------

- ORR of 20% in 45 evaluable patients vs historical 1-6% for standard of care; responses durable >6 months.
- Median PFS 5.5 months; 42% progression-free at 6 months; DCR 87%.
- Manageable safety, mostly Grade 1-2 diarrhea, fatigue, nausea; no significant liver toxicity despite 68% with liver metastases.
- Plans to meet FDA in H2 2026 for first-line registrational trial; accelerate pathways for 4th-line CRC and refractory Ewing sarcoma.
- BLA submitted to FDA for ozekibart in conventional chondrosarcoma in April 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000010/0002007919-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000010/inhibrx-20260421.htm
  HTML page:      https://secwatch.observer/filing/0002007919-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer